Israeli drug-maker Teva Pharmaceutical $TEVA Industries and Regeneron Pharmaceuticals Inc $REGN announced on Tuesday that they intend to jointly develop Regeneron’’s experimental new type of pain treatment. If the clinical trials are successful and approved by the regulators, they would jointly market the medicine, according to a Reuters’ report. The injectable treatment, branded as fasinumab, blocks Nerve Growth Factor (NGF), a protein responsible for transmitting pain signals. In the press release, the drug-makers said that its new mechanism of action could be a non-addictive a substitute to opioids. Currently, late-stage clinical trials are being conducted for evaluating its effectiveness to cure osteoarthritis pain and mid-stage studies for chronic low back pain.  Rival drug-makers Elli Lilly and Pfizer Inc. are planning to get regulatory approval for a similar drug, tanezumab, by 2018.